Remibrutinib ( LOU064 ) is a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. Remibrutinib ( LOU064 ) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. Remibrutinib ( LOU064 ) is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren’s syndrome.
For research use only. We do not sell to patients.